Teradyne Estimates Rise, but Its Buy Point Sits 34% Away

Investor's Business Daily reported on Aug. 24, 2026 that analysts are raising annual profit estimates on Teradyne, whose shares traded at 364.91 (-2.88%) at 18:03 GMT that day while the chart base carries a buy point of 487.91 — about 33.7% above the last trade.

Analysts are marking up their annual profit forecasts on chip-test equipment maker Teradyne, and Lumentum has returned to the group of stocks drawing upward earnings attention, according to research published by Investor's Business Daily. Scrubs and medical-apparel retailer Figs is among the other names on watch.

The estimate revisions and the tape are pointing in opposite directions. Teradyne (TER) last traded at 364.91, down 2.88% on the day as of 18:03 GMT on Aug. 24, 2026, after closing the prior session at 375.74. The chart pattern that analysts and technicians are watching carries a buy point of 487.91 — the price at which the stock would clear the top of its consolidation. That leaves a gap of 123.00 points, or roughly 33.7% above the last trade, an illustrative calculation from the quoted price and the stated buy point rather than a forecast.

A buy point that is nowhere near the current tape

A base, in the technical language IBD uses, is a period of sideways or downward consolidation after an advance. The buy point sits just above the pattern's high; a move through it on strong volume is treated as the signal. The distance matters here because 487.91 is not a near-term trigger. Teradyne would have to travel a long way before the setup is even in play.

The intraday action shows why the stock is being watched rather than bought. Teradyne's session range ran from 349.01 to 366.55, meaning the shares were about 4.6% off the day's low at the last print — again, arithmetic on the quoted figures, not a reported statistic. That is a wide swing for a single session and consistent with a name where the fundamental story and the price action have not yet synchronised.

Rising annual profit estimates are the fundamental half of that equation. When the sell side lifts full-year earnings-per-share forecasts, it usually reflects better order visibility, firmer pricing, or a mix shift toward higher-margin work. For a semiconductor test business, orders track the equipment spending cycle of chipmakers and their packaging partners, which is precisely where the market's attention has been concentrated.

Lumentum's return to the radar comes on a red day

Lumentum (LITE) is the second name flagged. The optical components supplier last traded at 832.34, down 3.97% from a prior close of 866.71, with a session range of 784.47 to 836.28. That is a steep single-day decline against a Nasdaq 100 (QQQ) that was off 0.84% at $707.47 — Lumentum fell several times harder than the tech benchmark on the day.

It is also, on the same figures, a stock that bounced hard off its own low: from 784.47 to 832.34 is a recovery of about 6.1% within the session, an illustrative move computed from the quoted range. Names with that kind of intraday amplitude tend to be where positioning is heavy and conviction is thin — which is a reasonable description of anything levered to optical interconnect demand in an AI-capex market.

The broader tape on Aug. 24 was mildly negative and split by style. The S&P 500 (SPY) traded at $763.55, down 0.28%, while the Dow 30 (DIA) was up 0.14% at $532.97. Growth and technology lagged; the more defensive, industrial-weighted index held up. That backdrop explains part of why both Teradyne and Lumentum were lower even as analysts were nudging numbers higher.

Figs sits at the other end of the market-cap and price scale

Figs (FIGS) was one of the few names on the watch list in the green, last at 14.83, up 1.02% from a prior close of 14.68, in a tight range of 14.63 to 14.95. The contrast with the two hardware names is stark: a single-digit-percentage share price with a narrow daily band, moving against a soft market rather than with it.

Direct-to-consumer apparel and semiconductor capital equipment have almost nothing in common as businesses, which is the point of a screen built on estimate revisions rather than sector. What links them is the direction of analyst numbers, not end demand. Investors reading a list like this should treat it as a starting universe, not a portfolio.

What separates a revision from a signal

Upward estimate revisions have a long record as a factor because they are persistent: analysts tend to move in the same direction more than once. But the revision is an input, not an outcome. Three things determine whether it turns into performance:

• Whether price confirms. Teradyne's buy point at 487.91 is the confirmation level technicians are waiting on. Until the stock trades there, the estimate story is unpriced by the chart.
• Whether the revision is broad. One firm raising a number is noise. A sustained series across the covering analysts is what the factor actually captures.
• Whether the sector cooperates. Both Teradyne and Lumentum fell on a day when the Nasdaq 100 was the weakest of the three major benchmarks. Estimate momentum has historically struggled to overcome a de-rating in the group.

What to watch from here

For Teradyne, the practical checkpoints are the low end of the current base and the 487.91 trigger. A stock that spends longer consolidating while estimates keep rising is compressing its valuation, which is generally constructive — but only if the base holds. Repeated tests of the lower boundary tend to weaken a pattern rather than build it.

For Lumentum, the question is whether the 3.97% drop is idiosyncratic or the front of a wider repricing in optical and networking hardware. The session's near-4% decline against a sub-1% fall in the Nasdaq 100 suggests something specific rather than a beta move, but a single day is not a trend.

For Figs, the setup is different again: a low-priced consumer name whose small gain on a down day says more about its lack of correlation to the AI complex than about any change in its own fundamentals.

The common thread across all three is that the earnings estimates are moving before the prices have. That gap is either an opportunity or a warning that the sell side is behind the market — and only the next few weeks of tape will say which.

Frequently asked questions

What is Teradyne's buy point and how far away is it?

The buy point on Teradyne's current base is 487.91. With the stock last trading at 364.91 as of 18:03 GMT on Aug. 24, 2026, that trigger sits 123.00 points higher — roughly 33.7% above the last price, based on arithmetic using those two figures. It is a longer-term chart level, not an imminent entry signal.

What does it mean when a stock is 'in a base'?

A base is a period of sideways or downward consolidation following a prior advance. Technicians measure the pattern's high and place a buy point just above it. Movement through that level on heavy volume is treated as confirmation that the consolidation has ended. Until then, the stock is considered to be building rather than breaking out.

Why are analysts raising Teradyne's earnings estimates?

Investor's Business Daily reported on Aug. 24, 2026 that analysts are lifting their annual profit estimates on Teradyne. The specific drivers behind those revisions were not detailed. As a semiconductor test equipment supplier, Teradyne's results generally track chipmakers' capital spending and the volume of devices requiring test at scale.

How did Lumentum trade on Aug. 24, 2026?

Lumentum last traded at 832.34, down 3.97% from a prior close of 866.71, with an intraday range of 784.47 to 836.28. That decline was substantially steeper than the Nasdaq 100's 0.84% fall the same session, though the stock had recovered meaningfully from its intraday low by the time of the last print.

What is Figs and why is it on the watch list?

Figs is a direct-to-consumer medical apparel company. It was named among the stocks on watch alongside Teradyne and Lumentum in research published on Aug. 24, 2026. Its shares last traded at 14.83, up 1.02% on the day, making it one of the few names on the list higher during a broadly softer session.

Do rising earnings estimates reliably predict stock gains?

Estimate revisions are a well-documented factor because analysts tend to move in the same direction repeatedly, so an initial upgrade often precedes further ones. But revisions are an input rather than a result. Price confirmation, breadth across the covering analysts, and the direction of the wider sector all determine whether higher estimates translate into returns.

Sources

• Teradyne, Lumentum Back On Analysts' Earnings Radar, With Two More Stocks On Watch — Investors Business Daily

Photo: ThisIsEngineering · Pexels Licence — source